Blog

Findings from the STEP trial revealed:

•  Patients who received Semaglutide in conjunction with behavioral intervention achieved an average weight loss of approximately 15%.
• Notably, individuals who lost around 10% of their body weight with Semaglutide experienced significant improvements in sugar control and reduced risk of heart disease. – Managing obesity, akin to diabetes, necessitates ongoing medication for chronic disease management.
• In contrast to other anti-obesity medications, there was no observed plateau phase following 28 weeks of Semaglutide treatment. Weight reduction in the Semaglutide-treated group persisted until the conclusion of the 68-week trial.
• Approximately one-third of Semaglutide recipients achieved a weight loss of approximately 20%, a result nearly comparable to that of bariatric surgery.

References:

https://obesitymedicine.org/blog/semaglutide-for-treatment-of-obesity/

Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022;5(9):e2231982. doi:10.1001/jamanetworkopen.2022.31982